{"id":50629,"date":"2025-12-13T23:14:04","date_gmt":"2025-12-13T15:14:04","guid":{"rendered":"https:\/\/flcube.com\/?p=50629"},"modified":"2025-12-13T23:14:05","modified_gmt":"2025-12-13T15:14:05","slug":"gsk-terminates-ideaya-synthetic-lethality-partnership-returns-two-clinical-programs","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=50629","title":{"rendered":"GSK Terminates Ideaya Synthetic Lethality Partnership, Returns Two Clinical Programs"},"content":{"rendered":"\n

UK biopharma GlaxoSmithKline plc<\/strong> (GSK, NYSE: GSK<\/a>) has initiated a breakup with Ideaya Biosciences<\/strong> (NASDAQ: IDYA), terminating their 2020 licensing agreement<\/strong> and returning two clinical\u2011stage synthetic lethality programs. The termination takes effect 90 days after written notice<\/strong>, with GSK transferring the remaining Werner Helicase and MAT2A assets back to Ideaya.<\/p>\n\n\n\n

Transaction Overview<\/h2>\n\n\n\n
Item<\/th>Details<\/th><\/tr><\/thead>
Original Agreement<\/strong><\/td>2020 synthetic lethality collaboration<\/td><\/tr>
Termination Date<\/strong><\/td>90 days following GSK\u2019s written notice (effective March\u202f2026)<\/td><\/tr>
Assets Returned<\/strong><\/td>Two clinical programs: Pol Theta Helicase inhibitor<\/strong> and MAT2A inhibitor<\/strong><\/td><\/tr>
Programs Exiting<\/strong><\/td>All three original assets (Werner Helicase already wound down)<\/td><\/tr>
Financial Terms<\/strong><\/td>No further financial obligations disclosed; original deal included undisclosed upfront and milestones<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Asset Portfolio Status<\/h2>\n\n\n\n
Program<\/th>Target<\/th>Stage<\/th>Status Post\u2011Termination<\/th><\/tr><\/thead>
Werner Helicase<\/strong><\/td>WRN (synthetic lethal in MSI\u2011H tumors)<\/td>Clinical<\/td>Previously returned; Ideaya retains full rights<\/td><\/tr>
Pol Theta Helicase<\/strong><\/td>POLQ (synthetic lethal in HRD tumors)<\/td>Phase\u202f1\/2<\/td>Transfer to Ideaya by March\u202f2026<\/td><\/tr>
MAT2A<\/strong><\/td>Methionine adenosyltransferase 2a<\/td>Pre\u2011clinical<\/td>Transfer to Ideaya by March\u202f2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Strategic Implications<\/h2>\n\n\n\n
Party<\/th>Impact<\/th><\/tr><\/thead>
GSK<\/strong><\/td>Portfolio rationalization; focus on internal oncology pipeline (including BCMA, GPRC5D assets); reduces R&D burn on early\u2011stage synthetic lethality programs<\/td><\/tr>
Ideaya<\/strong><\/td>Regains full global control<\/strong> of Pol Theta and MAT2A programs; can pursue new partnerships or self\u2011fund development; potential to monetize via alternative pharma collaborations<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Market Context<\/h2>\n\n\n\n

Synthetic lethality represents a $5\u20117\u202fbillion<\/strong> global market opportunity, anchored by PARP inhibitors. Next\u2011generation programs targeting Werner, Pol Theta, and MAT2A<\/strong> aim to address HRD\u2011positive and MSI\u2011H tumors resistant to existing therapies. Ideaya\u2019s regained assets position it to capture renewed investor interest in precision oncology<\/strong> partnerships.<\/p>\n\n\n\n

Forward\u2011Looking Statements<\/strong>
This brief contains forward\u2011looking statements regarding the termination timeline, asset transfer completion, and Ideaya\u2019s future partnership strategy. Actual results may differ due to regulatory complexities, competitive dynamics, or changes in strategic priorities.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

UK biopharma GlaxoSmithKline plc (GSK, NYSE: GSK) has initiated a breakup with Ideaya Biosciences (NASDAQ:…<\/p>\n","protected":false},"author":1,"featured_media":50633,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[278,184,1908,914],"class_list":["post-50629","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-glaxosmithkline","tag-gsk","tag-neurodawn-pharmaceutical","tag-nyse-gsk"],"yoast_head":"\nGSK Terminates Ideaya Synthetic Lethality Partnership, Returns Two Clinical Programs - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Neurodawn Pharmaceutical Co., Ltd. announced that its self\u2011developed Category\u202f1 chemical drug, Y\u20113 for Injection (generic name: Lobemilast), has had its New Drug Application (NDA) officially accepted by China\u2019s National Medical Products Administration (NMPA) for the treatment of Acute Ischemic Stroke (AIS). The drug targets the PSD95\u2011nNOS\/MPO pathway, a first\u2011in\u2011class mechanism globally.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=50629\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"GSK Terminates Ideaya Synthetic Lethality Partnership, Returns Two Clinical Programs\" \/>\n<meta property=\"og:description\" content=\"UK biopharma GlaxoSmithKline plc (GSK, NYSE: GSK) has initiated a breakup with Ideaya Biosciences (NASDAQ: IDYA), terminating their 2020 licensing agreement and returning two clinical\u2011stage synthetic lethality programs. The termination takes effect 90 days after written notice, with GSK transferring the remaining Werner Helicase and MAT2A assets back to Ideaya.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=50629\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-13T15:14:04+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-12-13T15:14:05+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1306.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50629#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50629\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"GSK Terminates Ideaya Synthetic Lethality Partnership, Returns Two Clinical Programs\",\"datePublished\":\"2025-12-13T15:14:04+00:00\",\"dateModified\":\"2025-12-13T15:14:05+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50629\"},\"wordCount\":317,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50629#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/1306.webp\",\"keywords\":[\"GlaxoSmithKline\",\"GSK\",\"Neurodawn Pharmaceutical\",\"NYSE: GSK\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=50629#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50629\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=50629\",\"name\":\"GSK Terminates Ideaya Synthetic Lethality Partnership, Returns Two Clinical Programs - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50629#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50629#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/1306.webp\",\"datePublished\":\"2025-12-13T15:14:04+00:00\",\"dateModified\":\"2025-12-13T15:14:05+00:00\",\"description\":\"Neurodawn Pharmaceutical Co., Ltd. announced that its self\u2011developed Category\u202f1 chemical drug, Y\u20113 for Injection (generic name: Lobemilast), has had its New Drug Application (NDA) officially accepted by China\u2019s National Medical Products Administration (NMPA) for the treatment of Acute Ischemic Stroke (AIS). The drug targets the PSD95\u2011nNOS\\\/MPO pathway, a first\u2011in\u2011class mechanism globally.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50629#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=50629\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50629#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/1306.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/1306.webp\",\"width\":1080,\"height\":608,\"caption\":\"GSK Terminates Ideaya Synthetic Lethality Partnership, Returns Two Clinical Programs\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50629#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"GSK Terminates Ideaya Synthetic Lethality Partnership, Returns Two Clinical Programs\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"GSK Terminates Ideaya Synthetic Lethality Partnership, Returns Two Clinical Programs - Insight, China's Pharmaceutical Industry","description":"Neurodawn Pharmaceutical Co., Ltd. announced that its self\u2011developed Category\u202f1 chemical drug, Y\u20113 for Injection (generic name: Lobemilast), has had its New Drug Application (NDA) officially accepted by China\u2019s National Medical Products Administration (NMPA) for the treatment of Acute Ischemic Stroke (AIS). The drug targets the PSD95\u2011nNOS\/MPO pathway, a first\u2011in\u2011class mechanism globally.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=50629","og_locale":"en_US","og_type":"article","og_title":"GSK Terminates Ideaya Synthetic Lethality Partnership, Returns Two Clinical Programs","og_description":"UK biopharma GlaxoSmithKline plc (GSK, NYSE: GSK) has initiated a breakup with Ideaya Biosciences (NASDAQ: IDYA), terminating their 2020 licensing agreement and returning two clinical\u2011stage synthetic lethality programs. The termination takes effect 90 days after written notice, with GSK transferring the remaining Werner Helicase and MAT2A assets back to Ideaya.","og_url":"https:\/\/flcube.com\/?p=50629","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-12-13T15:14:04+00:00","article_modified_time":"2025-12-13T15:14:05+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1306.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=50629#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=50629"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"GSK Terminates Ideaya Synthetic Lethality Partnership, Returns Two Clinical Programs","datePublished":"2025-12-13T15:14:04+00:00","dateModified":"2025-12-13T15:14:05+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=50629"},"wordCount":317,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=50629#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1306.webp","keywords":["GlaxoSmithKline","GSK","Neurodawn Pharmaceutical","NYSE: GSK"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=50629#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=50629","url":"https:\/\/flcube.com\/?p=50629","name":"GSK Terminates Ideaya Synthetic Lethality Partnership, Returns Two Clinical Programs - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=50629#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=50629#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1306.webp","datePublished":"2025-12-13T15:14:04+00:00","dateModified":"2025-12-13T15:14:05+00:00","description":"Neurodawn Pharmaceutical Co., Ltd. announced that its self\u2011developed Category\u202f1 chemical drug, Y\u20113 for Injection (generic name: Lobemilast), has had its New Drug Application (NDA) officially accepted by China\u2019s National Medical Products Administration (NMPA) for the treatment of Acute Ischemic Stroke (AIS). The drug targets the PSD95\u2011nNOS\/MPO pathway, a first\u2011in\u2011class mechanism globally.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=50629#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=50629"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=50629#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1306.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1306.webp","width":1080,"height":608,"caption":"GSK Terminates Ideaya Synthetic Lethality Partnership, Returns Two Clinical Programs"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=50629#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"GSK Terminates Ideaya Synthetic Lethality Partnership, Returns Two Clinical Programs"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1306.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/50629","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=50629"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/50629\/revisions"}],"predecessor-version":[{"id":50634,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/50629\/revisions\/50634"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/50633"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=50629"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=50629"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=50629"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}